InvestorsObserver
Sign Up Login

NVIV Invivo Therapeutics Holdings Cor

$0.93 $0.00 (-0.05%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

NVIV Stock Analysis Overview

What this means: Invivo Therapeutics Holdings Cor (NVIV) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives NVIV a rank of 5. Our methodology considers analysis of the company's financial situation and how it has traded recently. NVIV rank of 5 means that it ranks below 95% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

NVIV Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

NVIV Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

NVIV Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

NVIV Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

NVIV Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

NVIV Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

NVIV Stock Analysis Overview

What this means: Invivo Therapeutics Holdings Cor (NVIV) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives NVIV a rank of 5. Our methodology considers analysis of the company's financial situation and how it has traded recently. NVIV rank of 5 means that it ranks below 95% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full NVIV report

NVIV Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

NVIV Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

NVIV Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

NVIV Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

NVIV Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

NVIV Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Invivo Therapeutics Holdings Cor (NVIV) Analyst Forecast

NVIV Price, Volume, Earnings, and Dividend Date

  • Last Price $0.93
  • Previous Close $0.93
  • Change $0.00
  • Open $0.97
  • Volume 29,336
  • Avg. Volume (100-day) 95,308
  • Market Cap 2,658,785
  • Days Range 0.92 - 0.97
  • 52-week Range 0.91 - 13.77
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 0.6
  • EPS —
  • Earnings Date 03/27/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 4.647
  • PEG Ratio —

Invivo Therapeutics Holdings Cor (NVIV) Company Description

InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

Invivo Therapeutics Holdings Cor (NVIV) Stock Chart

View Interactive NVIV chart

My Watchlists

Top Stocks in Biotechnology